The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC).
Andrea Borghese Apolo
No relevant relationships to disclose
Howard L. Parnes
No relevant relationships to disclose
Ravi Amrit Madan
No relevant relationships to disclose
James L. Gulley
No relevant relationships to disclose
John Joseph Wright
No relevant relationships to disclose
Jean H. Hoffman-Censits
No relevant relationships to disclose
Nancy Ann Dawson
No relevant relationships to disclose
Jane B. Trepel
No relevant relationships to disclose
Kattie Khadar
No relevant relationships to disclose
Jeffrey Schlom
No relevant relationships to disclose
Maria Merino
No relevant relationships to disclose
Mark Raffeld
No relevant relationships to disclose
Seth M. Steinberg
No relevant relationships to disclose
Peter L. Choyke
No relevant relationships to disclose
Maria Liza Lindenberg
No relevant relationships to disclose
Les Folio
No relevant relationships to disclose
Piyush K. Agarwal
No relevant relationships to disclose
William Douglas Figg
No relevant relationships to disclose
Donald P. Bottaro
No relevant relationships to disclose
William L. Dahut
No relevant relationships to disclose